Novel Biomarkers in Prediction of Heart Failure Related Outcomes: From Bench to BedsideBerezin AE1,2*
- *Corresponding Author:
- Berezin AE
Vita-Center, Zaporozhye and Senior Consultant of Therapeutic Unit
Internal Medicine Department, State Medical University of Zaporozhye, Ukraine
E-mail: [email protected]
Received date: March 21, 2017; Accepted date: April 06, 2017; Published date: April 13, 2017
Citation: Berezin AE (2017) Novel Biomarkers in Prediction of Heart Failure Related Outcomes: From Bench to Bedside. Intern Med 7:236. doi: 10.4172/2165-8048.1000236
Copyright: © 2017 Berezin AE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Heart failure (HF) remains a global burden for patients with established cardiovascular (CV) disease. It has been postulated that underlying mechanisms of nature evolution of HF might be identified by measurement of some biomarker reflected various pathophysiological stages of cardiac dysfunction. In this way, cardiac biomarkers affected biomechanical stress, cardiac injury, fluid overload, inflammatory reaction, may be useful for prediction of development, progression, and prognosis of HF. The short communication is depicted to discussion around perspectives to use in routine HF clinical practice new biomarkers, i.e. procalcitonin, copeptin, heart-type fatty acidbinding protein; growth differentiation factor 15. It has concluded that these biomarkers are needed to be investigated in details, while there is suggestion that multiple biomarker models would be better in prediction HF evolution and outcomes than even single brand new biomarker.